Cue Biopharma, Inc. expected to post a loss of $1.69 a share - Earnings Preview

Cue Biopharma

07/08/2026 22:30

Cue Biopharma, Inc. CUE.OQ CUE.O is expected to  show a rise in quarterly revenue when it reports  results on August 10 (estimated) for the period ending June 30 2026
The Boston Massachusetts-based  company is expected to report a 1.6% increase in revenue to $3 million from $2.95 million a year ago, according to the estimate from one analyst, based on LSEG data.
​LSEG's mean analyst estimate for Cue Biopharma, Inc. is for a loss of $1.69 per share. 
The one available analyst rating on the shares is "buy".  
The average consensus recommendation for the biotechnology & medical research peer group is also "Buy".​
Wall Street's median 12-month price target for Cue Biopharma, Inc. is $115.00, about 325.8% above its last closing price of $27.01
This summary was machine generated August 7 at 21:30 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)